Topic: Erbitux

Biothera Releases Colorectal Cancer Study Results at ASCO

Drugs.com - 981 days ago
ORLANDO, Fla.--(BUSINESS WIRE)--May 29, 2009 - The combination of Imprime PGG?, Erbitux? (cetuximab) and Camptosar? (irinotecan) nearly doubled the overall response rate of second- and third-line metastatic colorectal cancer patients compared with the standard of care of cetuximab and irinotecan alone, according ...